scholarly journals Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals

JGH Open ◽  
2020 ◽  
Vol 4 (4) ◽  
pp. 713-721
Author(s):  
Riccardo Nevola ◽  
Luca Rinaldi ◽  
Letizia Zeni ◽  
Ferdinando C Sasso ◽  
Pia C Pafundi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Direct Acting Antivirals ◽  
Hepatitis C Infection ◽  
Virus Clearance ◽  
Renal Changes ◽  
Direct Acting

scholarly journals Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Eric R. Yoo ◽  
Ryan B. Perumpail ◽  
George Cholankeril ◽  
Aijaz Ahmed
Keyword(s):  
Down Syndrome ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Direct Acting Antivirals ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Favorable Safety

Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past, interferon-based therapy for chronic hepatitis C infection in patients with Down syndrome was noted to have lower efficacy and potentially higher risk of adverse effects. Recently, the treatment for chronic hepatitis C has been revolutionized with the introduction of interferon-free direct acting antivirals with favorable safety, tolerability, and efficacy profile. Based on our experiences, the newly approved sofosbuvir-based direct acting antiviral therapy is well tolerated and highly efficacious in this subpopulation of hepatitis C virus infected patients with Down syndrome.

scholarly journals A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection

2012 ◽  
Vol 8 (1) ◽  
pp. e1002339 ◽  
Author(s):  
Bambang S. Adiwijaya ◽  
Tara L. Kieffer ◽  
Joshua Henshaw ◽  
Karen Eisenhauer ◽  
Holly Kimko ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Dynamic Model ◽  
Chronic Hepatitis C ◽  
Direct Acting Antivirals ◽  
Hepatitis C Infection ◽  
Treatment Regimens ◽  
Viral Dynamic ◽  
Direct Acting

scholarly journals Direct-Acting Antiviral–Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C

2016 ◽  
Vol 214 (12) ◽  
pp. 1965-1974 ◽  
Author(s):  
Julia Hengst ◽  
Christine Susanne Falk ◽  
Verena Schlaphoff ◽  
Katja Deterding ◽  
Michael Peter Manns ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Direct Acting Antiviral ◽  
Virus Clearance ◽  
Direct Acting

scholarly journals Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C

PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0229994
Author(s):  
Sheng Feng Lin ◽  
Shui-Yi Tung ◽  
Kuo-Liang Wei ◽  
Chien-Hung Chen ◽  
Tsung-Hui Hu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Clinical Utility ◽  
Core Antigen ◽  
Direct Acting Antivirals ◽  
Virus Core ◽  
Antigen Assay ◽  
Direct Acting

scholarly journals Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek

2015 ◽  
Vol 156 (21) ◽  
pp. 841-848
Author(s):  
Gábor Horváth ◽  
Tünde Halász ◽  
Mihály Makara ◽  
Béla Hunyady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Viral Response ◽  
Virus Hepatitis ◽  
Direct Acting Antivirals ◽  
Screening Programs ◽  
Viral Response ◽  
Direct Acting

Chronic hepatitis C, without treatment, can cause liver cirrhosis, liver failure and liver cancer. The availability of new oral direct acting antivirals, such as the protease inhibitors simeprevir, asunaprevir and paritaprevir, the NS5A inhibitors daclatasvir, ledipasvir, and ombitasvir, the polymerase inhibitors Sofosbuvir and dasabuvir have resulted an enormous progress in the treatment of chronic hepatitis C, leading to >90% sustained viral response rates. Even the hard-to-treat or previously treatment ineligible patients can be cured with the combination of these drugs. Furthermore the treatment duration is much shorter, and the side effects are minimal. Today, treatment of all hepatitis C virus infected patients is recommended, and the best choices are the interferon-free options. Eradication of hepatitis C virus has become realistic, however, appropriate screening programs are mandatory to achieve this goal. Orv. Hetil., 2015, 156(21), 841–848.

Sign in / Sign up

Export Citation Format

Share Document